Amgen Adopts A Two-Price Strategy For The U.S. ’s First Marketed Humira-Referenced Biosimilar, Amjevita
In the case of Amjevita, the two-price approach highlights the lack of transparency in the healthcare system as well as the incredibly confusing way in which drugs are priced in the U.S. Rebates obfuscate an already bewildering and fragmented pricing maze. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 1, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news

Doc Re-Used Nasal Surgery Devices; Humira Patent Game; Nonprofit Hospital Tactics
(MedPage Today) -- Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week. Doc Re-Used Devices for Nasal Surgeries North Carolina otolaryngologist Anita Louise Jackson... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 1, 2023 Category: American Health Source Type: news

First Humira Biosimilar Launches in US First Humira Biosimilar Launches in US
Amgen ' s Amjevita will be offered at 5% and 55% below Humira ' s list price, but patients may not benefit from the more significant discount.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - January 31, 2023 Category: Internal Medicine Tags: Rheumatology News Source Type: news

AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
AbbVie's (ABBV) two-decade Humira monopoly came to an end Tuesday after Amgen (AMGN) launched its biosimilar knockoff at a 55% discount to the original. But AbbVie stock was mostly unmoved. The biosimilar called Amjevita is the first to hit the U.S. market. But through deals with AbbVie, a handful…#abbvie #humira #amgen #amgn #amjevita #murdogordon #abbviestock #richardgonzalez #organon #ogn (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2023 Category: Consumer Health News Source Type: news

Blockbuster AbbVie drug Humira to face competition in US for first time
Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 31, 2023 Category: Pharmaceuticals Source Type: news

AMJEVITA ™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.(1,2) (Source: World Pharma News)
Source: World Pharma News - January 31, 2023 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

'Go big or go home': How a Peninsula biotech looks to win in Humira biosimilar 'feeding frenzy'
The company won't launch its lookalike version of AbbVie's Humira until July, though it was approved by the FDA in December 2021. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 30, 2023 Category: American Health Authors: Ron Leuty Source Type: news

Over $100B in savings? Why the incoming Humira biosimilars will take time to catch on
Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers all the big issues faced by biopharma. This transcript has been edited for brevity and clarity. I think 2022 had to be one of the worst years ever…#johncarroll #catalent #alessandromaselli #federalreserve #unlock (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2023 Category: Consumer Health News Source Type: news

Sunday links: the tools we create
Markets 11 things that zero interest rates enabled including the rise of Cathie Wood. (youngmoney.co) The 'nice-to-have' economy is already in recession. (wsj.com) Why you need a well-articulated investment strategy to ride out tough times. (contessacapitaladvisors.com) AI Everyone is watching for…#cathiewood #aieveryone #google #generativeai #companiesabbvie #abbv #humira #russian #romanabramovich #bnpl (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2023 Category: Consumer Health News Source Type: news

How a Drug Company Made $114 Billion by Gaming the U.S. Patent System
AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. In 2016, a blockbuster drug called Humira was poised to become a lot less valuable. The key patent on the best-selling anti-inflammatory medication, used to…#humira #abbvie #amgensamjevita #ssrhealth #medicare #bristolmyerssquibb #astrazeneca #rachelsachs #washingtonuniversity #stlouis (Source: Reuters: Health)
Source: Reuters: Health - January 28, 2023 Category: Consumer Health News Source Type: news

AbbVie Stock: To Buy Or Not To Buy (NYSE:ABBV) | Seeking Alpha
AbbVie (NYSE:ABBV) has been a quality power healthcare stock in Rose's Income Garden "RIG" portfolio since 2015. I added to it, on and off through the years, as the price was volatile and many become concerned it had taken on too much debt to acquire Pharmacyclics, a leading hematological oncology…#fg #valueline #roseincomegarden #abbvie #skyrizi #analyzersoftwaretool #allergan #humira #botox #rinvoq (Source: Reuters: Health)
Source: Reuters: Health - January 18, 2023 Category: Consumer Health News Source Type: news

Stocks making the biggest moves midday: Bed Bath & Beyond, Tesla, Expedia and more
Check out the companies making headlines in midday trading. Meme stocks — A group of so-called meme stocks skyrocketed Wednesday as retail investors jumped into speculative trades again. Bed Bath & Beyond rallied 38% to trigger the trend in morning trading Wednesday. Shares of GameStop, the…#humira #poolcorp #austin #levistrauss #bankofamerica #davinci #google #goldmansachs #memestocks #gamestop (Source: Reuters: Health)
Source: Reuters: Health - January 11, 2023 Category: Consumer Health News Source Type: news

What to Know About Infusion Therapy for IBD
The human gastrointestinal tract can be a hostile place for visitors. It’s filled with digestive acids and microorganisms that rapidly break down swallowed bits of food, and it can be just as rough on non-food molecules. That includes some of the latest drugs for the treatment of inflammatory bowel disease (IBD). “Some medications that target the immune system don’t work if they’re swallowed because your gut would digest them like a piece of steak,” says Dr. Gilaad Kaplan, a gastroenterologist, IBD researcher, and professor of medicine at the University of Calgary in Canada. “You have to...
Source: TIME: Health - January 10, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Source Type: news

Humira Competitors Have CVS Wrestling With Complex Calculations
(Source: Reuters: Health)
Source: Reuters: Health - January 6, 2023 Category: Consumer Health News Source Type: news

Deep Dive: Buy shares of only the strongest companies to make money in 2023, including ‘the kings of cash flow,’ says this five-star fund manager
Depending on your perspective as an investor, 2022 has either been a perfect storm or a perfect opportunity. The Federal Reserve’s rapid increase in interest rates and other tightening moves to fight inflation have pushed stock and bond prices significantly lower. If you lose sleep over short-term…#adams #abbvieincabbv #appleincaapl #humira #abbvies #alphabetsclassa #spx #federalreserves #gregadams #abbvie (Source: Reuters: Health)
Source: Reuters: Health - December 27, 2022 Category: Consumer Health News Source Type: news